NEURITE NETWORKS: A KEY TARGET FOR NEUROGENERATIVE DISEASES
Neuronal injury or neurogenerative diseases often feature perturbations in neurite networks, and CNS-targeting therapeutics often aim to restore/repair those networks.
Our Ready-2-Go Assay Service quantitatively assesses the effect of therapeutics on established networks of human, iPSC-derived, glutamatergic neurons to provide insights into the toxicity profiles of your therapeutic candidates.
KEY FEATURES
Uses human, iPSC-derived neurons
Quantitative, morphological measurements of neurites and soma
Only 6-8 weeks from assay to report
Option to bundle R2G Services or transition to Custom Services
AVOID SPECIES DIFFERENCES WITH HUMAN, iPSC-DERIVED NEURONS
The use of animal models or immortalized cell lines limits clinical translatability. We use human, iPSC-derived glutamatergic neurons to help bridge the gap between the bench and clinic.
RELATED READY-2-GO SERVICES
Browse related Ready-2-Go assay offerings. For custom assays, check out our Custom Services.
R2G NEUROTOXICITY
Multiplexed readouts of viability and apoptosis.
Learn more
R2G NEURONAL MITOCHONDRIAL HEALTH
Multiplexed readouts of mitochondrial health.
Learn more
R2G MICROGLIA PHAGOCYTOSIS
Measure uptake of a fluorescent bacterial bioparticle by human, iPSC-derived human microglia.
Learn more
R2G NEURITE OUTGROWTH
Quantification of neurite outgrowth using human, iPSC-derived neurons.
Learn more